BACKGROUND: Trim28 appears up-regulated in many cancers. RESULTS: In early stage lung tumors high Trim28 correlates with increased overall survival and Trim28 reduces cell proliferation in model lung cancer cell lines through E2F interactions. CONCLUSION: Trim28 may have a tumor suppressing role in the early stages of lung cancer. SIGNIFICANCE: These results suggest a complex role for Trim28 in lung cancer. Trim28 is a poorly understood transcriptional co-factor with pleiotropic biological activities. Although Trim28 mRNA is found in many studies to be up-regulated in both lung and breast cancer tissues relative to normal adjacent tissue, we found that within a panel of early-stage lung adenocarcinomas high levels of Trim28 protein correlate with better overall survival. This surprising observation suggests that Trim 28 may have anti-proliferative activity within tumors. To test this hypothesis, we used shRNAi to generate Trim28-knockdown breast and lung cancer cell lines and found that Trim28 depletion led to increased cell proliferation. Likewise, overexpression of Trim28 led to decreased cell proliferation. Confocal microscopy indicated co-localization of E2F3 and E2F4 with Trim28 within the cell nucleus, and co-immunoprecipitation assays demonstrated that Trim28 can bind both E2F3 and E2F4. Trim28 overexpression inhibited the transcriptional activity of E2F3 and E2F4, whereas Trim28 deficiency enhanced their activity. Co-immunoprecipitations further indicated that Trim28 bridges an interaction between E2Fs 3 and 4 and HDAC1. Promoter-reporter assays demonstrated that the ability of HDAC1 to repress E2F3 and E2F4-driven transcription is dependent on Trim28. Trim28 depletion increased E2F3 and E2F4 DNA binding activity, as measured by chromatin-immunoprecipitation (ChIP) assays while simultaneously reducing HDAC1 binding. Finally, ChIP-ReChIP experiments demonstrated that Trim/E2F complexes exist on several E2F-regulated promoters. Taken together, these results suggest that Trim28 has anti-proliferative activity in lung cancers via repression of members of the E2F family that are critical for cell proliferation.
BACKGROUND:Trim28 appears up-regulated in many cancers. RESULTS: In early stage lung tumors high Trim28 correlates with increased overall survival and Trim28 reduces cell proliferation in model lung cancer cell lines through E2F interactions. CONCLUSION:Trim28 may have a tumor suppressing role in the early stages of lung cancer. SIGNIFICANCE: These results suggest a complex role for Trim28 in lung cancer. Trim28 is a poorly understood transcriptional co-factor with pleiotropic biological activities. Although Trim28 mRNA is found in many studies to be up-regulated in both lung and breast cancer tissues relative to normal adjacent tissue, we found that within a panel of early-stage lung adenocarcinomas high levels of Trim28 protein correlate with better overall survival. This surprising observation suggests that Trim 28 may have anti-proliferative activity within tumors. To test this hypothesis, we used shRNAi to generate Trim28-knockdown breast and lung cancer cell lines and found that Trim28 depletion led to increased cell proliferation. Likewise, overexpression of Trim28 led to decreased cell proliferation. Confocal microscopy indicated co-localization of E2F3 and E2F4 with Trim28 within the cell nucleus, and co-immunoprecipitation assays demonstrated that Trim28 can bind both E2F3 and E2F4. Trim28 overexpression inhibited the transcriptional activity of E2F3 and E2F4, whereas Trim28 deficiency enhanced their activity. Co-immunoprecipitations further indicated that Trim28 bridges an interaction between E2Fs 3 and 4 and HDAC1. Promoter-reporter assays demonstrated that the ability of HDAC1 to repress E2F3 and E2F4-driven transcription is dependent on Trim28. Trim28 depletion increased E2F3 and E2F4 DNA binding activity, as measured by chromatin-immunoprecipitation (ChIP) assays while simultaneously reducing HDAC1 binding. Finally, ChIP-ReChIP experiments demonstrated that Trim/E2F complexes exist on several E2F-regulated promoters. Taken together, these results suggest that Trim28 has anti-proliferative activity in lung cancers via repression of members of the E2F family that are critical for cell proliferation.
Authors: David C Schultz; Kasirajan Ayyanathan; Dmitri Negorev; Gerd G Maul; Frank J Rauscher Journal: Genes Dev Date: 2002-04-15 Impact factor: 11.361
Authors: G Leone; R Sears; E Huang; R Rempel; F Nuckolls; C H Park; P Giangrande; L Wu; H I Saavedra; S J Field; M A Thompson; H Yang; Y Fujiwara; M E Greenberg; S Orkin; C Smith; J R Nevins Journal: Mol Cell Date: 2001-07 Impact factor: 17.970
Authors: Jun Hou; Joachim Aerts; Bianca den Hamer; Wilfred van Ijcken; Michael den Bakker; Peter Riegman; Cor van der Leest; Peter van der Spek; John A Foekens; Henk C Hoogsteden; Frank Grosveld; Sjaak Philipsen Journal: PLoS One Date: 2010-04-22 Impact factor: 3.240
Authors: David G Beer; Sharon L R Kardia; Chiang-Ching Huang; Thomas J Giordano; Albert M Levin; David E Misek; Lin Lin; Guoan Chen; Tarek G Gharib; Dafydd G Thomas; Michelle L Lizyness; Rork Kuick; Satoru Hayasaka; Jeremy M G Taylor; Mark D Iannettoni; Mark B Orringer; Samir Hanash Journal: Nat Med Date: 2002-07-15 Impact factor: 53.440
Authors: Michael A Mandell; Ashish Jain; John Arko-Mensah; Santosh Chauhan; Tomonori Kimura; Christina Dinkins; Guido Silvestri; Jan Münch; Frank Kirchhoff; Anne Simonsen; Yongjie Wei; Beth Levine; Terje Johansen; Vojo Deretic Journal: Dev Cell Date: 2014-08-07 Impact factor: 12.270
Authors: Joseph B Addison; Colton Koontz; James H Fugett; Chad J Creighton; Dongquan Chen; Mark K Farrugia; Renata R Padon; Maria A Voronkova; Sarah L McLaughlin; Ryan H Livengood; Chen-Chung Lin; J Michael Ruppert; Elena N Pugacheva; Alexey V Ivanov Journal: Cancer Res Date: 2014-11-24 Impact factor: 12.701
Authors: Carolin Bürck; Andreas Mund; Julia Berscheminski; Lisa Kieweg; Sarah Müncheberg; Thomas Dobner; Sabrina Schreiner Journal: J Virol Date: 2015-11-04 Impact factor: 5.103